论文信息 - 1237MO SAKK 16/14: Anti-PD-L1 antibody durvalumab in addition to neoadjuvant chemotherapy in patients with stage IIIA (N2) non-small cell lung cancer (NSCLC) – A multicenter single-arm phase II trial - 字舞流文

1237MO SAKK 16/14: Anti-PD-L1 antibody durvalumab in addition to neoadjuvant chemotherapy in patients with stage IIIA (N2) non-small cell lung cancer (NSCLC) – A multicenter single-arm phase II trial

C. Britschgi | D. Betticher | M. Joerger | S. Savic Prince | A. Zippelius | A. Ochsenbein | M. Pless | P. Froesch | N. Mach | M. Früh | W. Janthur | C. Rusterholz | M. Mark | S. Peters | E. Eboulet | A. Bettini | S. Rothschild | C. Waibel | M. Gonzalez | G. Godar